Endovascular Development accepted to Uppsala Innovation Centre Business Accelerator

 
Two new companies have now been accepted to UICs accelerator program which supports innovative companies in Uppsala to scale up and increase their growth or grow internationally.  

The program offers companies a unique access to tailored business support and an investment of SEK 500,000. The companies accepted are Endovascular Development and Stardots.

The UIC Business Accelerator business development program accepts innovative companies that are ready to scale up their business further or find a new market. During the program, the companies gain access to specialised knowledge based on the company's unique needs in areas such as law, finance, marketing, leadership or technology. The life science company Endovascular Development and the E-health company Stardots have now been accepted.

Endovascular Development has developed a new Guidewire Fixator which enables safer surgery and reduces operating time along with improving treatments in endovascular surgery.

Stardots, AI-TRUST™ will utilize the cloud and AI to deliver software-as-a-drug for those suffering from Parkinson’s Disease. The digital health platform will significantly improve PD patients’ quality of life, substantially reduce treatment cost and offer an aid to clinical trials for MedTech and pharmaceutical companies.

"These two companies are examples of how UIC attracts innovation that can really make a difference for society as a whole and people as individuals. It will be very interesting to support the companies, partly through the accelerator but also through the investment offered by Linnéa Capital, says Patric Karlsson, Program Manager at UIC.
UIC Business Accelerator runs for two to three years and is for innovative growth companies. The companies are offered tailor-made business development support by hand-picked business coaches from the business community, with specialised skills based on the company's unique needs.

Companies accepted to the accelerator program are also offered an investment of SEK 500,000 from Linnéa Capital. The aim is to strengthen the companies' financial situation and increase growth opportunities. 
 
For more information:
Patric Karlsson, Program Manager and Program Manager UIC Business Accelerator
 UICTel:  +46 705 45 36 75E-mail:  patric.karlsson@uic.se
Vedrana Ilic, kommunikatörUICTel: 0708-51 97 04E-post: 
vedrana.ilic@uic.se
About UIC
UIC (Uppsala Innovation Centre) is one of the country's foremost business incubators and accelerators and is ranked by UBI Global among the world's top 5 best public business incubators. UIC offers tailored business development support, knowledge and networking to innovative startups and growth companies that want to develop their business, scale up or reach an international market. UIC does not take any ownership stakes and is industry independent. UIC works closely with the business community through, for example, a large network of business coaches from the business world and some twenty UIC partners, all of whom contribute to the development of uic companies together with UIC. UIC operates in Uppsala County and Södertälje Municipality. The owners of UIC are equally STUNS, Uppsala Municipality, SLU Holding and Uppsala University Holding. UIC is part of Vinnova's Incubation Support – Excellence program.  www.uic.se

Re-classification of LGF now complete and looking to the future

Endovab is very happy to announce that the medical device re-classification process now is completed: The Liungman Guidewire Fixator CE mark Class 3 (MDD) is valid until May 2024.

We look forward to continuing to supply this key tool to all endovascular centres in Europe, which will help them make interventions in the aorta and the peripheral artery safer and in a shorter time.


The LGF clinical study is now published in INNOVATION - Technologies and Techniques in Cardiothoracic and Vascular Surgery. 
 
The study was conducted as a separate trial in ten patients undergoing endovascular aortic repair. The LGF was deployed in the Hypogastric artery from a cross over access. 3N of tension was applied to the guidewire to verify guidewire fixation. The LGF was then retrieved and the artery was inspected for any sign of trauma using angiography and a 30 days post operative CT-scan. 
 
Deployment was uneventful in all ten patients. Retrieval according to the intended instruction for use was performed in nine of the patients. In one patient, a coaxial catheterization was necessary. All devices withstood a retention force of 3 N.

 “This study was aimed to investigate and verify the pre-clinical results from porcine models, and the results are very similar, no dissection or vessel trauma so far. The device has been designed to produce an evenly distributed, radial force against the vessel wall, which reduces the risk for dissection. In my opinion dissection often occurs due to pointy tools, often guidewires, that penetrates the initima.” Says Krister Liungman, Founder and Head of Clinical at Endovab
 

Läs hela inlägget »
16/05/2018
Fenestrated aortic arch repair, from a pure femoral access!
13/11/2017
Dr David Deaton joins Endovab
09/11/2017
Clinical results presented at the Veith Symposium!
05/10/2017
Preloaded f-EVAR with pre-lining of fenestrations on table


The LGF clinical study is now published in INNOVATION - Technologies and Techniques in Cardiothoracic and Vascular Surgery. 
 
The study was conducted as a separate trial in ten patients undergoing endovascular aortic repair. The LGF was deployed in the Hypogastric artery from a cross over access. 3N of tension was applied to the guidewire to verify guidewire fixation. The LGF was then retrieved and the artery was inspected for any sign of trauma using angiography and a 30 days post operative CT-scan. 
 
Deployment was uneventful in all ten patients. Retrieval according to the intended instruction for use was performed in nine of the patients. In one patient, a coaxial catheterization was necessary. All devices withstood a retention force of 3 N.

 “This study was aimed to investigate and verify the pre-clinical results from porcine models, and the results are very similar, no dissection or vessel trauma so far. The device has been designed to produce an evenly distributed, radial force against the vessel wall, which reduces the risk for dissection. In my opinion dissection often occurs due to pointy tools, often guidewires, that penetrates the initima.” Says Krister Liungman, Founder and Head of Clinical at Endovab
 

Read the full post »
16/05/2018
Fenestrated aortic arch repair, from a pure femoral access!
13/11/2017
Dr David Deaton joins Endovab
09/11/2017
Clinical results presented at the Veith Symposium!
05/10/2017
Preloaded f-EVAR with pre-lining of fenestrations on table

ARCHIVE

LATEST NEWS

Copyright © 2019. Endovascular Development AB. All Rights Reserved.